Proportion of subjects in mCRE-MITT Population at TOC visit with response of Success, defined as subject whose gram-neg antimicrobials to treat infection are not altered (except dose adjust or modification of Best Available Therapy based on susceptibility within 72hrs of first dose) post randomization due to concerns of microbiological/clinical failure, or tolerability, &: cUTI/AP; EMA - Microbiological eradication. FDA - Overall Success (clinical cure & microbiological eradication). Eradication defined as the demonstration that the bacterial pathogen(s) found at baseline is reduced to <103 CFU/mL urine (EMA) & <104 CFU/mL urine (FDA). Clinical cure defined as complete resolution or significant improvement of the baseline signs & symptoms, no further antimicrobial warranted. HABP & VABP; Clinical cure (as above) Bacteremia; Overall Success (as above, except eradication defined as the demonstration that bacterial pathogen(s) found at baseline is absent with repeat culture)